FTRE — Fortrea Holdings Inc.

Is FTRE overbought or oversold? Here is the current MarketMoodz read.

Healthcare · Biotechnology

Overbought As of October 8, 2026

Fortrea Holdings Inc. (FTRE) currently reads Overbought on the MarketMoodz overbought/oversold meter, as of October 8, 2026. The Healthcare name (Biotechnology) last closed at $20.37.

See all overbought Healthcare stocks →

AI analysis

Fortrea benefits from durable demand for outsourced drug development and manufacturing, with structural tailwinds from oncology and next‑gen biologics partnerships. Revenue visibility from multi‑year contracts and the company’s integrated service offering are strengths, while margin expansion is feasible as utilization and mix improve. Key near‑term catalysts include contract awards, successful program ramps and positive inspection outcomes; primary vulnerabilities are execution on capacity, customer concentration and competitive pricing pressure. Monitor backlog trends, utilization, margin dynamics and any regulatory or inspection developments to track upside vs downside scenarios.

Key factors

  • Favorable secular demand for CDMO and drug-development outsourcing from biopharma, particularly in oncology and next‑gen modalities
  • Potential for multi-year contracts and backlog to provide revenue visibility and recurring cash flow
  • Operational scale and integrated service offering that can win larger, end-to-end programs versus smaller niche providers
  • Market tone is mildly risk-on and selectively favoring growth/healthcare outsourcing names, which can support near-term multiples
  • Partnerships and commercialization tailwinds in oncology and next‑gen biologics increase addressable market for manufacturing and development services
  • Opportunity for margin expansion through utilization gains, mix shift to higher‑value services, and post‑integration efficiencies

Risks

  • Execution risk on large program ramps, capacity utilization and integration of acquired assets
  • Client concentration or the loss/delay of a major sponsor program that materially affects near-term revenue
  • Manufacturing quality, regulatory inspection findings or supply‑chain disruptions that can delay shipments and revenue recognition
  • Pricing pressure from customers and competitive intensity in the CDMO space compressing margins
  • Macro slowdown that reduces biotech funding and outsourcing budgets, slowing deal flow and order timing
  • Policy or legal developments (e.g., drug‑pricing rules) that indirectly affect biopharma spend patterns and CDMO demand

See today's live rating, score and targets

Members see the live hourly rating for FTRE — the numeric AI score plus targets and entry zones — while this public page updates nightly.

Start the 14-day trial

This page is for informational purposes only and is not investment, financial, tax, or legal advice. Ratings and research outputs can be wrong, incomplete, or stale. Past performance does not guarantee future results. Always do your own research and consider consulting a qualified professional.